Summary & Overview

CPT 0273U: Versiti Fibrinolytic Disorder Panel, NGS + aCGH

CPT code 0273U identifies the Versiti™ Fibrinolytic Disorder Panel, a proprietary laboratory test that uses next-generation sequencing of eight genes plus array Comparative Genomic Hybridization of one gene to support diagnosis of symptomatic patients and evaluation of familial risk for delayed bleeding disorders caused by hyperfibrinolysis. As a PLA code, 0273U is unique to a single manufacturer and laboratory and is used to capture a specific complex genetic testing service that may have distinct coverage and billing considerations nationally.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for hyperfibrinolysis testing, how PLA coding affects billing and reporting, and the types of service settings where this test is typically performed. The publication outlines common modifiers and operational details relevant to laboratory billing, and highlights what to expect in payer engagement and claims processing for proprietary genetic panels. Data not available in the input: payer-specific coverage policies, associated taxonomies, ICD-10 diagnoses, related codes, and service line details.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0273UCPTProprietary Laboratory AnalysesGenetic TestingNext-Generation SequencingaCGHFibrinolytic DisorderLaboratory BillingMolecular Diagnostics

Billing Code Overview

CPT code 0273U is a Proprietary Laboratory Analyses (PLA) code that applies only to the unique Versiti™ Fibrinolytic Disorder Panel offered by Versiti™ Diagnostic Laboratories. The test combines next-generation sequencing (NGS) analysis of eight genes with array Comparative Genomic Hybridization (aCGH) of one gene to aid in diagnosis of symptomatic patients or evaluation of familial risk for delayed bleeding disorders caused by hyperfibrinolysis.

Service type: Genetic/molecular diagnostic laboratory testing using NGS plus aCGH
Typical site of service: Clinical diagnostic laboratory or reference testing laboratory; specimen collection can occur in outpatient clinics, phlebotomy centers, hospitals, or other ambulatory settings using blood, buccal swab, or amniotic fluid

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult or pediatric individual referred to a specialty hematology or genetic testing laboratory for evaluation of unexplained bleeding, recurrent mucocutaneous hemorrhage, postpartum or post-procedural excessive bleeding, or a family history of delayed bleeding disorders. The clinician orders the Versiti™ Fibrinolytic Disorder Panel (0273U) when standard coagulation studies (PT, aPTT, platelet count, fibrinogen) are non-diagnostic but clinical suspicion remains for disorders of fibrinolysis or when a familial mutation is suspected and cascade testing is indicated. A specimen (blood, buccal swab, or amniotic fluid) is collected in the clinic or ambulatory infusion/hematology lab and sent to Versiti™ Diagnostic Laboratories. The laboratory performs next-generation sequencing (NGS) of eight genes and array comparative genomic hybridization (aCGH) of one gene to detect sequence variants and copy number changes associated with hyperfibrinolytic bleeding phenotypes. Results are reported to the ordering hematologist or genetic counselor, who integrates molecular findings with clinical history to guide diagnosis, family risk assessment, and management planning. Typical sites of service include outpatient hematology clinics, genetic counseling centers, hospital outpatient labs, and specialized pathology or molecular diagnostic laboratories.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier; standard service

Taxonomy Code	Specialty	Notes
207RH0000X	Hematology	Hematologists commonly order and interpret fibrinolytic disorder panels.
2080P0207X	Medical Genetics	Medical geneticists and genetic counselors manage interpretation and family risk assessment.
207L00000X	Clinical Pathology	Molecular pathology labs and clinical pathologists oversee NGS and aCGH testing.
207L00010X	Molecular Genetics Laboratory	Laboratories with molecular genetics specialty perform and report the test.
2085R0202X	Pediatric Hematology-Oncology	Pediatric hematologists order testing for congenital or inherited fibrinolytic disorders in children.

ICD-10 Code	Description	Clinical Relevance
`D68.32`	Primary hyperfibrinogenolysis	Directly related to disorders of fibrinolysis assessed by the panel.
`D68.9`	Coagulation defect, unspecified	Used when a specific bleeding disorder has not been identified and molecular testing is pursued.
`R58`	Hemorrhage, not elsewhere classified	Indicates active or recent bleeding prompting diagnostic evaluation including this panel.
`O72.3`	Delayed and secondary postpartum hemorrhage	Postpartum bleeding cases may prompt evaluation for underlying fibrinolytic disorders.
`Z14.89`	Genetic carrier status for other specified genetic diseases	Used when testing is performed for familial risk assessment or carrier detection.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Often performed prior to `0273U` when a blood specimen is required for NGS and aCGH.
`99183`	Physician counseling for genetic testing (billing may vary)	Used when pre-test or post-test genetic counseling is billed separately by the provider; payer policies vary.
`81211`	BRCA1 gene analysis, full sequence; (example of single-gene sequencing)	Represents the type of single-gene sequencing tests that may be ordered in parallel or historically compared; clinically similar molecular methodology.
`81479`	Unlisted molecular pathology procedure	Used when a specific proprietary PLA code is not accepted by a payer and an unlisted molecular pathology code is required for claims processing.
`88385`	Microdissection for molecular testing	Performed in the molecular pathology workflow when tumor or selected cells require enrichment prior to NGS, if applicable.
`0051U`	Proprietary lab test example (PLA)	Other PLA codes may be billed in the same claim when multiple proprietary assays from a lab are ordered concurrently; used to reflect similar PLA reporting workflows.

OpenPayer